We are very glad that we have this opportunity for considering our manuscript for publishing in the *World Journal of Psychiatry*. The revision process and all suggestions have greatly improved our manuscript. We tried to answer all reviewers' comments point by point and marked them in the text in yellow. New references were also added and marked in the text in yellow.

#### Answers to Reviewer's #1 comments

1. Introduction: Kindly refer to the sentence: It is the most common chronic disabling disease in young adults and middle-aged people..... The authors cited the reference: Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor B V., Thompson AJ. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014; 83: 1022-1024. [PMID: 25200713 DOI: 10.1212/WNL.00000000000000768]. However the article cited mentions: "Multiple sclerosis (MS) is one of the world's most common neurologic disorders, and in many countries it is the leading cause of nontraumatic neurologic disability in young adults." The authors interpretation about MS as most common chronic disabling disease in young adults and middle-aged people, is not correct. The authors may rephrase their sentence.

This sentence is now rephrased per the reviewer's recommendation into:" It is one of the most common neurologic disorders and represents the most common cause of acquired neurological disability among young adults, affecting 2.5 million people worldwide".

2. Introduction: Kindly refer to the sentence: MS patients are two or three times more likely than general population to suffer from mood and mental health disorders..... It would be better if the authors will report it as... two to three times... instead of two or three times.

This sentence is now revised per the reviewer's recommendation. We changed the sentence: "MS patients are two or three times more likely than general population to suffer from mood and mental health disorders" to "MS patients are two to three times more likely than the general population to suffer from mood and mental health disorders.

3. Introduction: Paragraph 2 and 3 looks disjointed.

Thank you for this suggestion. Now we reordered paragraphs 2 and 3.

4. The authors need to discuss about the genetics of multiple sclerosis and its possible association with psychosis.

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00255

1/fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027932/ https://www.frontiersin.org/articles/10.3389/fimmu.2017.00425/full https://www.ncbi.nlm.nih.gov/books/NBK470155/

We additionally discussed the multiple sclerosis genetics and possible association with psychosis (section Neuroimmunological aspects of MS and psychosis, paragraph 2). We also added new references and marked them in the text in yellow (reference number 16, 17, 18, 19).

5. The authors also need to discuss about role of immunomodulators used in the treatment of MS, in causation of psychosis.

Now, we discuss the role of immunomodulators used in the treatment of MS, in the causation of psychosis (section Known facts and treatment challenges in MS-related psychosis, paragraph 1). We also added new references and marked them in the text in yellow (reference number 60, 61, 62).

6. The authors should discuss about practice implications of treating psychosis in MS (Safety and efficacy of antipsychotic drugs).

Per the reviewer's recommendation, we discussed the practice implications of treating psychosis in MS (safety and efficacy of antipsychotic drugs) (section Known facts and treatment challenges in MS-related psychoses, paragraph 5). We also added new references and marked them in the text in yellow (reference number 82, 83, 84, 85, 86).

7. Conclusion is lengthy. It does not require references. It should be the summary and implications on the theme.

We have now excluded citations from the Conclusion, summarized the content of the manuscript, and altogether shorter the Conclusion section. Hope that this section is now greatly improved per the reviewer's suggestions.

### Answers to Reviewer's #2 comments

This minireview paper summarizes recent advances in the explanation of comorbidity between psychosis and multiple sclerosis. Authors analyze the shared and distinct immuno-pathogenetic pathways and mechanisms which underpin the two conditions and their exacerbations. Implications for pharmacological treatment strategies are reviewed as well. The manuscript may benefit from inclusion of few more sources, in order to exceed the usually considered minimum of 80 titles for minireview. Those sources may be focused on the issue of psychiatric validity and construction of nomothetic networks for diagnosis, which may approximate psychiatry to the disciplinary context of medicine.

We have now added the references per the requirements of both reviewers and especially discussed the importance of nomothetic networks in this context (section Neuroimmunological aspects of MS and psychosis, paragraph 6, reference number 52, in summary, more than 80 titles).

The search strategy should be outlined in the introduction, including key words, covered time frame and data bases.

Per the reviewer's recommendation, now we added in the Introduction a search strategy, including keywords, covered time frame, and databases, considering also the special requirements of the mini-review (section Introduction, paragraph 5).

We have checked and corrected all technical aspects for the manuscript preparation, as required below:

#### **ABBREVIATIONS**

In general, do not use non-standard abbreviations, unless they appear at least two times in the text preceding the first usage/definition. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, and mAb, do not need to be defined and can be used directly.

The basic rules on abbreviations are provided here:

- (1) Title: Abbreviations are not permitted. Please spell out any abbreviation in the title.
- **(2) Running title:** Abbreviations are permitted. Also, please shorten the running title to no more than 6 words.

- (3) Abstract: Abbreviations must be defined upon first appearance in the Abstract. Example 1: Hepatocellular carcinoma (HCC). Example 2: Helicobacter pylori (H. pylori).
- **(4) Key Words:** Abbreviations must be defined upon first appearance in the Key Words.
- **(5) Core Tip:** Abbreviations must be defined upon first appearance in the Core Tip. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)
- **(6) Main Text:** Abbreviations must be defined upon first appearance in the Main Text. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)
- (7) **Article Highlights:** Abbreviations must be defined upon first appearance in the Article Highlights. Example 1: Hepatocellular carcinoma (HCC).

Example 2: *Helicobacter pylori* (*H. pylori*)

- **(8) Figures:** Abbreviations are not allowed in the Figure title. For the Figure Legend text, abbreviations are allowed but must be defined upon first appearance in the text. Example 1: A: Hepatocellular carcinoma (HCC) biopsy sample; B: HCC-adjacent tissue sample. For any abbreviation that appears in the Figure itself but is not included in the Figure Legend textual description, it will be defined (separated by semicolons) at the end of the figure legend. Example 2: BMI: Body mass index; US: Ultrasound.
- **(9) Tables:** Abbreviations are not allowed in the Table title. For the Table itself, please verify all abbreviations used in tables are defined (separated by semicolons) directly underneath the table. Example 1: BMI: Body mass index; US: Ultrasound.

# **6 EDITORIAL OFFICE'S COMMENTS**

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

## (1) Science editor:

The manuscript has been peer-reviewed, and it's ready for the first decision. Language Quality: Grade B (Minor language polishing) Scientific Quality: Grade B (Very good)

# (2) Company editor-in-chief:

I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Psychiatry, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022. If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be republished; and correctly indicating the reference source and copyrights. For example, "Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable. Before final acceptance, when revising the manuscript, the author must supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply a new tool, the RCA. RCA is an artificial intelligence technologybased open multidisciplinary citation analysis database. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our **RCA** database for more information at: https://www.referencecitationanalysis.com/.

### 7 STEPS FOR SUBMITTING THE REVISED MANUSCRIPT

# **Step 1:** Author Information

Please click and download the <u>Format for authorship</u>, <u>institution</u>, <u>and corresponding author guidelines</u>, and further check if the authors names and institutions meet the requirements of the journal.

# Step 2: Manuscript Information

Please check if the manuscript information is correct.

# **Step 3:** Abstract, Main Text, and Acknowledgements

- (1) Guidelines for revising the content: Please download the guidelines for Original articles, Review articles, or Case Report articles for your specific manuscript type (Minireviews) at: <a href="https://www.wjgnet.com/bpg/GerInfo/291">https://www.wjgnet.com/bpg/GerInfo/291</a>. Please further revise the content your manuscript according to the Guidelines and Requirements for Manuscript Revision.
- **(2) Format for Manuscript Revision:** Please update the format of your manuscript according to the Guidelines and Requirements for Manuscript Revision and the Format for Manuscript Revision. Please visit <a href="https://www.wjgnet.com/bpg/GerInfo/291">https://www.wjgnet.com/bpg/GerInfo/291</a> for the article type-specific guidelines and formatting examples.
- **(3) Requirements for Article Highlights:** If your manuscript is an Original Study (Basic Study or Clinical Study), Meta-Analysis, or Systemic Review, the "Article Highlights" section is required. Detailed writing requirements for the "Article Highlights" can be found in the Guidelines and Requirements for Manuscript Revision.
- **(4) Common issues in revised manuscript.** Please click and download the <u>List of common issues in revised manuscripts by authors and comments</u> (PDF), and revise the manuscript accordingly.

## **Step 4:** References

Please revise the references according to the <u>Format for References Guidelines</u>, and be sure to edit the reference using the reference auto-analyser.

## **Step 5:** Footnotes and Figure Legends

(1) Requirements for Figures: Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file, and submit as "82790-Figures.pptx" on the system. The figures should be uploaded

to the file destination of "Image File". Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022. Please click to download the sample document: <u>Download</u>.

**(2) Requirements for Tables:** Please provide decomposable Tables (in which all components are movable and editable), organize them into a single Word file, and submit as "82790-Tables.docx" on the system. The tables should be uploaded to the file destination of "Table File".

**Reminder:** Please click and download the <u>Guidelines for preparation of bitmaps</u>, <u>vector graphics</u>, and tables in revised manuscripts (PDF), and prepare the figures and tables of your manuscript accordingly.

# **Step 6:** Automatically Generate Full-Text Files

Authors cannot replace and upload the "Manuscript File" separately. Since we only accept a manuscript file that is automatically generated, please download the "Full Text File" or click "Preview" to ensure all the contents of the manuscript automatically generated by the system are correct and meet the requirements of the journal. If you find that there is content that needs to be modified in the Full-Text File, please return to the corresponding step(s), modify and update the content, and save. At this point, you then have to click the "Save & Continue" button in Step 5 and the F6Publishing system will automatically regenerate the Full-Text File, and it will be automatically stored.

## **Step 7:** Upload the Revision Files

For all required accompanying documents (listed below), you can begin the uploading process *via* the F6Publishing system. Then, please download all the uploaded documents to ensure all of them are correct.

- (1)82790-AnsweringReviewers
- (2)82790-AudioCoreTip
- (3)82790-Conflict-of-InterestDisclosureForm
- (4)82790-CopyrightLicenseAgreement
- (5) 82790-Approved Grant Application Form(s) or Funding Agency Copy of any ApprovalDocument(s)
- (6)82790-Non-NativeSpeakersofEnglishEditingCertificate
- (7)82790-Video
- (8)82790-ImageFile
- (9)82790-TableFile
- (10) 82790-Supplementary Material

If your manuscript has supportive foundations, the approved grant application form(s) or funding agency copy of any approval document(s) must be provided. Otherwise, we will delete the supportive foundations.

If your manuscript has no "Video" or "Supplementary Material", you do not need to submit those two types of documents.

### **8 COPYRIGHT LICENSE AGREEMENT**

All authors should accept and sign the Copyright License Agreement (CLA), following the link sent in individual emails to each author. After all authors have accepted and signed their respective CLA, the Corresponding Author is responsible for downloading the signed CLA by clicking on the "Download" button in the CLA page, re-storing it as "PDF", and then uploading it to the file destination of "Copyright License Agreement". If any of the authors do not accept to sign the CLA, the manuscript will not be accepted for publication.

**Reminder:** If any of the authors do not receive the email of CLA, please check the spam folder. If the author still can't find the email, please contact us via email at: submission@wjgnet.com.

### 9 CONFLICT-OF-INTEREST DISCLOSURE FORM

Please click and download the fillable <u>ICMJE Form for Disclosure of Potential Conflicts of Interest</u> (PDF), and fill it in. The Corresponding Author is responsible for filling out this form. Once filled out completely, the Conflict-of-Interest Disclosure Form should be uploaded to the file destination of 'Conflict-of-Interest Disclosure Form'.

Best regards,

Jin-Lei Wang, Company Editor-in-Chief, Editorial Office

# **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** j.l.wang@wjgnet.com

Help desk: <a href="https://www.f6publishing.com/helpdesk">https://www.f6publishing.com/helpdesk</a>

Online Submission: <a href="https://www.f6publishing.com/">https://www.f6publishing.com/</a>

# https://www.wjgnet.com

# About Baishideng

Baishideng Publishing Group (Baishideng), founded on January 15, 1993, is a biomedical publishing company accredited by the Committee on Publication Ethics, editing and publishing more than 47 academic journals in Chinese and English. All of the Baishideng's academic journals are published using an open access and singleblind external peer-review model, with some high-quality academic journals being included in the Science Citation Index Expanded, Emerging Sources Citation Index, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis (RCA), and other important databases. Baishideng relies its industry leading F6Publishing system, which features functionalities covering the entire publication process, from manuscript submission to online publishing, including an article quality tracking system, author evaluation system, and reader evaluation system. In addition, Baishideng has the world's only RCA system, an open and transparent high-quality academic article evaluation service platform for various categories that is freely available to authors and readers. The functions of RCA include Find an Article, Find a Category, Find a Journal, Find a Scholar, and Find an Academic Assistant.